
The First Orally Delivered Cell Therapy for the Treatment of Inflammatory Bowel Disease

Grant Award Details

The First Orally Delivered Cell Therapy for the Treatment of Inflammatory Bowel Disease

Grant Type: Quest - Discovery Stage Research Projects

Grant Number: DISC2-12126

Project Objective: To complete activities leading to the declaration of a single oral cell therapy for inflammatory bowel disease [IBD] comprised of encapsulated adult mesenchymal stem cells.

Investigator:

Name:	Aline Betancourt
Institution:	Vitabolus, Inc.
Type:	PI

Disease Focus: Inflammatory bowel disease, Intestinal Disease, Metabolic Disorders

Human Stem Cell Use: Adult Stem Cell

Award Value: \$249,000

Status: Active

Grant Application Details

Application Title: The First Orally Delivered Cell Therapy for the Treatment of Inflammatory Bowel Disease

Public Abstract:**Research Objective**

The goal of this project is to develop the first ORAL cell therapy as a breakthrough treatment for inflammatory bowel disease [IBD].

Impact

We engineered a new way to deliver cells ORALLY instead of by injection. In doing so, we will better reach the inflamed tissues and provide a much-needed new treatment for those afflicted with IBD.

Major Proposed Activities

- We expect that from these studies an optimal dose and dosing regimen for the oral cell therapy will be established and will help build our clinical target product profile.
- We expect that we will further characterize the anti-inflammatory mechanism of action of the oral cell therapy.
- We will also establish the biodistribution of the orally delivered cells to further gain support for advancement of our breakthrough IBD therapy towards clinical studies.
- We will collect all of the information needed to request an FDA INTERACT meeting.

Statement of Benefit to California:

The current standard of care works in only a third of the inflammatory bowel disease [IBD] patients. IBD incidence is growing in California and elsewhere, and there is no known cure. Cell-based therapy is considered the next generation treatment approach for IBD. An orally delivered cell therapy simultaneously solves some of the hurdles of this promising industry while offering a much needed novel therapeutic to IBD patients.

Source URL: <https://www.cirm.ca.gov/our-progress/awards/first-orally-delivered-cell-therapy-treatment-inflammatory-bowel-disease>